Aller au contenu principal
Profil bibliographique

Katsuyuki Hamada

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

102Publications signalées
1740Citations signalées
2Affiliations récentes

Les institutions déclarées

Les domaines associés

Virus-based gene therapy researchCancer Research and TreatmentsViral Infectious Diseases and Gene Expression in InsectsCancer-related Molecular PathwaysEndometrial and Cervical Cancer Treatments

Les publications récentes

Accès ouvert 2021 article OpenAlex

Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector

Wataru Matsunaga, Katsuyuki Hamada, Masatoshi Tagawa, Takao Morinaga et autres

BACKGROUND: The clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) is thought to have promising clinical potential. However, the off-target effects of Cas9 are a major concern for its application. Therefore, we hypothesized that the adverse effects of off-target gene editing …

jp (code pays fourni par la source)

3 citations Anticancer Research
Accès ouvert 2021 article OpenAlex

Microbial Antigen-Presenting Extracellular Vesicles Derived from Genetically Modified Tumor Cells Promote Antitumor Activity of Dendritic Cells

Tomoko Ito, Kikuya Sugiura, Aya Hasegawa, Wakana Ouchi et autres

Tumor-derived extracellular vesicles (EVs), as tumor vaccines, carry tumor-associated antigens (TAAs), and were expected to transfer TAAs to antigen-presenting cells. However, treatment with tumor-derived EVs exhibited no obvious antitumor effect on the established tumors, likely due to their immuno-suppressive functions, and also …

jp (code pays fourni par la source)

15 citations Pharmaceutics
Accès ouvert 2018 article OpenAlex

Cloning of carrier cells infected with oncolytic adenovirus driven by midkine promoter and biosafety studies

Katsuyuki Hamada, Soichi Takagi, Hajime Kuboshima, Hideaki Shimada et autres

BACKGROUND: A549 carrier cells infected with oncolytic adenovirus can induce complete tumor reduction of subcutaneous ovarian tumors but not intraperitoneal disseminated ovarian tumors. This appears to be a result of the insufficient antitumor effect of A549 carrier cells. Therefore, in the present …

jp, us (code pays fourni par la source)

4 citations The Journal of Gene Medicine
Accès ouvert 2017 article OpenAlex

Laparoscopic treatment of a case of cesarean scar syndrome

Toshiaki Yasuoka, Toru Fujioka, Megumi Ueno, Sakiko Murakami et autres

BACKGROUND: With the increase in the cesarean section rate, the complications associated with cesarean section wounds have also increased. The presence of a cesarean scar defect and diverticulum has recently been identified as a source of persistent, irregular vaginal bleeding, menstrual pain, …

jp (code pays fourni par la source)

1 citation JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY
Accès ouvert 2016 article OpenAlex

Enantioselective synthesis of beta-amino acid derivatives via nickel-promoted regioselective carboxylation of ynamides and rhodium-catalyzed asymmetric hydrogenation

Nozomi Saito, Iman Abdullah, Kayoko Hayashi, Katsuyuki Hamada et autres

We succeeded in the development of a new method for enantioselective synthesis of alpha-substituted-beta-amino acid derivatives. Thus, nickel(0)-promoted carboxylation of ynamide gave the alpha-substituted-beta-aminoacrylate derivative in a highly regioselective manner. Then, rhodium-catalyzed asymmetric hydrogenation of the a-substituted beta-aminoacrylate produced the corresponding alpha-substituted …

jp (code pays fourni par la source)

0 citations Institutional Repositories DataBase (IRDB)
Accès ouvert 2016 article OpenAlex

420. Improvement of Antitumor Activity in Intraperitoneal Ovarian Cancer Model by a Noble Cloned Carrier Cell Infected with Oncolytic Adenovirus

Katsuyuki Hamada, Kazuko Takagi, Takashi Sugiyama

Infection inhibition of virus by antiviral antibodies is one of the major problems that cancer gene therapy has never shown the significant antitumor activity in human clinical trial. Oncolytic adenovirus-infected A549 carrier cells develop cell fragments and exosomes containing oncolytic adenoviral particles …

jp (code pays fourni par la source)

0 citations Molecular Therapy
Accès ouvert 2016 article OpenAlex

Immune activation during the implantation phase causes preeclampsia-like symptoms via the CD40–CD40 ligand pathway in pregnant mice

Keiichi Matsubara, Yuko Matsubara, Miki Mori, Yuka Uchikura et autres

The CD40 ligand (CD40L) is expressed by T cells and has a critical role in immune system regulation. Interventions targeting CD40L interactions following embryo implantation represent an approach to preventing preeclampsia (PE). To better understand the role of CD40L in PE, we …

jp (code pays fourni par la source)

15 citations Hypertension Research
Accès ouvert 2016 article OpenAlex

A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity

Kaname Nosaki, Katsuyuki Hamada, Yuto Takashima, Miyako Sagara et autres

Although various therapies are available to treat cancers, including surgery, chemotherapy, and radiotherapy, cancer has been the leading cause of death in Japan for the last 30 years, and new therapeutic modalities are urgently needed. As a new modality, there has recently …

jp (code pays fourni par la source)

42 citations Molecular Therapy — Oncolytics
Accès ouvert 2015 article OpenAlex

437. Biosafety After the Injection of Carrier Cells Infected With Oncolytic Adenovirus

Katsuyuki Hamada, Kazuko Takagi, Hiroshi Itoh, Kenzaburo Tani et autres

Although replication-competent viruses have been developed to treat cancers, their cytotoxic effects are insufficient, since infection with them is inhibited by generation of neutralizing antibodies. To address this limitation, we developed a carrier cell system to deliver a replication-competent adenovirus. Carrier cells …

jp (code pays fourni par la source)

0 citations Molecular Therapy
Accès ouvert 2015 article OpenAlex

631. Novel Polymer-Coated Stealth Oncolytic Measles Virus Overcame Immune Suppression and Induced Stronger Antitumor Activity

Kaname Nosaki, Katsuyuki Hamada, Yuto Takishima, Miyako Sagara et autres

Background: Although there have recently been much progress in cancer treatment including surgery, chemotherapy and radiotherapy, cancers have long been the leading cause of death in Japan in the last 30 years and the development of new therapeutic modalities is imminently required. …

jp (code pays fourni par la source)

0 citations Molecular Therapy
Accès ouvert 2014 article OpenAlex

Biosafety studies of carrier cells infected with a replication-competent adenovirus introduced by IAI.3B promoter

Katsuyuki Hamada, Toshiro Shirakawa, Shuji Terao, Akinobu Gotoh et autres

The use of carrier cells infected with oncolytic viruses in cancer gene therapy is an attractive method because it can overcome viral immunogenicity and induce tumor immunity and significant antitumor activity. To enable human clinical trials of this treatment, acute and chronic …

jp, cn (code pays fourni par la source)

1 citation Molecular Therapy — Methods & Clinical Development
Accès ouvert 2013 article OpenAlex

Atypical carcinoid of the uterine cervix with aggressive clinical behavior: A case report

Toshiaki Yasuoka, Hisashi Hashimoto, Katsuyuki Hamada, Toru Fujioka et autres

•We herein report a case of a 44-year-old Japanese woman diagnosed with stage IB1 atypical carcinoid of the uterine cervix.•After radical hysterectomy, she developed recurrence with aggressive clinical behavior, resistance to CPT-11 + cisplatin and paclitaxel + CBDCA chemotherapy.

jp (code pays fourni par la source)

10 citations Gynecologic Oncology Case Reports

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.